Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026NEW YORK, NY - April 2, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORTNEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
2 Cash-Heavy Stocks Worth Your Attention and 1 We Find RiskyA surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026NEW YORK, NY - April 1, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCNEW YORK and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (
NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff DeadlinesNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Navan, Inc. (
NASDAQ: NAVN) and Corcept Therapeutics Incorporated (
NASDAQ: CORT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March RallyIn a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (
NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF (
NYSEARCA: XBI) and the Nasdaq Biotechnology Index (
NASDAQ: IBB) struggled to find their footing in late March 2026, dropping
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market VolatilityIn a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500 and Nasdaq Composite indices tumbled over 1.5% due to lingering inflation concerns and a surprise hawkish pivot
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (
NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
3 Reasons to Avoid CORT and 1 Stock to Buy InsteadShareholders of Corcept would probably like to forget the past six months even happened. The stock dropped 56.3% and now trades at $36.31. This was partly dr...
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Corcept Therapeutics Incorporated (
NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session (ACC 2026).
Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan FoxNEW YORK, NY - March 28, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan FoxNEW YORK, NY - March 27, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology BreakthroughThe biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (
NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the company’s market capitalization, was triggered by a "perfect storm" of positive regulatory developments and breakthrough clinical
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of LifyorliMarch 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (
NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of Lifyorli™ (relacorilant) for platinum-resistant ovarian cancer (PROC). This approval, coming four months ahead of its scheduled PDUFA date, marks Corcept's transition from a niche endocrinology player into [...]
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORTNEW ORLEANS, March 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
